Franklin Templeton Inks Quill Deal for Investment Commentary

Using Narrative Science's Quill product will help Franklin Templeton to scale its commentary production and focus on more complex analysis.

Quill ink and parchment

Officials say Narrative Science's Quill, which went live at Franklin Templeton last month, will free up time and resources, allowing the firm's investment experts to focus on producing more complex analysis and forward looking perspectives.

"Quill Portfolio Commentary enables our team to scale delivery of more routine fund content and data updates across multiple strategies and markets, while allowing us to dedicate more of our expert resources to authoring in-depth investment perspectives and

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

Register for free

Access two articles, our IMD and Waters Wraps, plus a member newsletter. Find out more.

All fields are mandatory unless otherwise highlighted.

This address will be used to create your account

A tech revolution in an old-school industry: FX

FX is in a state of transition, as asset managers and financial firms explore modernizing their operating processes. But manual processes persist. MillTechFX’s Eric Huttman makes the case for doubling down on new technology and embracing automation to increase operational efficiency in FX.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here